Sung T, Miller D C, Hayes R L, Alonso M, Yee H, Newcomb E W
Department of Pathology, New York University School of Medicine, NY 10016, USA.
Brain Pathol. 2000 Apr;10(2):249-59. doi: 10.1111/j.1750-3639.2000.tb00258.x.
Classification of high grade astrocytomas of children into genetic subtypes similar to the adult remains to be defined. Here we report an extensive characterization of 29 high grade pediatric astrocytomas, 7 WHO grade III and 22 WHO grade IV, for genetic alterations frequently observed in high grade adult astrocytomas occurring in either the p53/MDM2/p14ARF or Rb/CDK4/p16INK4a tumor suppressor pathways. In addition, we have assessed the contribution of EGFR overexpression and amplification and LOH for chromosome 10, two genetic alterations commonly associated with the development of de novo adult glioblastoma for their roles in the development of de novo astrocytomas of childhood. Our results suggest two major differences in the genetic pathway(s) leading to the formation of de novo high grade astrocytomas in children compared with those of the adult. Our findings show preferential inactivation of the p53 tumor suppressor pathway in >95% of pediatric astrocytomas versus inactivation of the Rb tumor suppressor pathway in <25% of the same tumors. In addition, de novo high grade pediatric astrocytomas lack amplification of the EGFR gene compared with EGFR amplification in one-third of adult glioblastomas. Since drug treatments and gene therapy strategies exploit specific genetic alterations in tumor cells, our findings have important implications for the future development of treatments for high grade pediatric astrocytomas.
将儿童高级别星形细胞瘤分类为与成人相似的基因亚型仍有待确定。在此,我们报告了对29例儿童高级别星形细胞瘤(7例WHO III级和22例WHO IV级)的广泛特征分析,这些肿瘤发生在p53/MDM2/p14ARF或Rb/CDK4/p16INK4a肿瘤抑制途径中,而这些途径在成人高级别星形细胞瘤中经常观察到基因改变。此外,我们评估了表皮生长因子受体(EGFR)过表达和扩增以及10号染色体杂合性缺失(LOH)的作用,这两种基因改变通常与成人原发性胶质母细胞瘤的发生相关,以探讨它们在儿童原发性星形细胞瘤发生中的作用。我们的结果表明,与成人相比,儿童原发性高级别星形细胞瘤形成的遗传途径存在两个主要差异。我们的研究结果显示,超过95%的儿童星形细胞瘤中p53肿瘤抑制途径优先失活,而在相同肿瘤中,不到25%的肿瘤中Rb肿瘤抑制途径失活。此外,与三分之一的成人胶质母细胞瘤中EGFR扩增相比,儿童原发性高级别星形细胞瘤缺乏EGFR基因扩增。由于药物治疗和基因治疗策略利用肿瘤细胞中的特定基因改变,我们的研究结果对儿童高级别星形细胞瘤未来治疗的发展具有重要意义。